美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Alpha Tau Medical Warrant

0.9774

-0.0226-2.26%

成交量：4.83萬

成交額：4.82萬

市值：6,879.00萬

市盈率：-1.87

高：1.00

開：1.00

低：0.9747

收：1.00

52周最高：1.50

52周最低：0.1300

股本：7,038.06萬

流通股本：7,038.06萬

量比：1.66

換手率：0.07%

股息：- -

股息率：- -

每股收益(TTM):-0.5213

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Alpha Tau Medical將在ASCO GI 2026研討會上公布兩項新積極成果展示蒙特利爾胰腺癌Alpha Dart®研究的免疫保護與高疾病控制率

Alpha Tau向FDA提交Alpha Dart®治療複發性皮膚鱗狀細胞癌的首個上市前審批模塊

Alpha Tau獲得FDA批准啓動局部復發前列腺癌患者試驗

Alpha Tau Medical成功治療美國多中心胰腺癌臨床試驗首例患者

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/DRTSW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DRTSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRTSW\",,,,,undefined,":{"symbol":"DRTSW","market":"US","secType":"STK","nameCN":"Alpha Tau Medical Warrant","latestPrice":0.9774,"timestamp":1772830800000,"preClose":1,"halted":0,"volume":48319,"delay":0,"changeRate":-0.022599999999999953,"floatShares":70380571,"shares":70380571,"eps":-0.5213,"marketStatus":"盤後交易","change":-0.0226,"latestTime":"03-06 17:05:50 EST","open":1,"high":1,"low":0.9747,"amount":48151.3265,"amplitude":0.0253,"askPrice":1.21,"askSize":100,"bidPrice":0.392,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.5213,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1772845200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":1,"latestTime":"09:25 EST","volume":100,"amount":102,"timestamp":1772807127716,"change":0.02,"changeRate":0.02,"amplitude":0},"volumeRatio":1.65893},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRTSW\",,,,,undefined,":{"symbol":"DRTSW","floatShares":70380571,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.65893,"shares":70380571,"dividePrice":0,"high":1,"amplitude":0.0253,"preClose":1,"low":0.9747,"week52Low":0.13,"pbRate":"--","week52High":1.5,"institutionHeld":0,"latestPrice":0.9774,"committee":0.333333,"eps":-0.5213,"divideRate":0,"volume":48319,"delay":0,"ttmEps":-0.5213,"open":1,"prevYearClose":0.34,"prevWeekClose":1.21,"prevMonthClose":1.21,"prevQuarterClose":0.34,"fiveDayClose":1.21,"twentyDayClose":0.8602,"sixtyDayClose":0.338},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DRTSW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DRTSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DRTSW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DRTSW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1152568891","title":"Alpha Tau Medical將在ASCO GI 2026研討會上公布兩項新積極成果 展示蒙特利爾胰腺癌Alpha Dart®研究的免疫保護與高疾病控制率","url":"https://stock-news.laohu8.com/highlight/detail?id=1152568891","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152568891?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 22:08","pubTimestamp":1767708521,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical宣布，其即将在ASCO GI 2026研讨会上展示的两项研究取得了新的积极结果。这些成果重点揭示了Alpha Dart®蒙特利尔胰腺癌研究中体现的免疫保护特性与卓越疾病控制效果。\n研究数据显示，该疗法在维持患者免疫系统功能的同时，实现了较高的疾病控制水平。这一突破为胰腺癌治疗领域提供了新的方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTSW","BK4082","DRTS"],"gpt_icon":0},{"id":"1128236953","title":"Alpha Tau向FDA提交Alpha Dart®治療複發性皮膚鱗狀細胞癌的首個上市前審批模塊","url":"https://stock-news.laohu8.com/highlight/detail?id=1128236953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128236953?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 22:06","pubTimestamp":1767622002,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical已向美国食品药品监督管理局（FDA）提交了Alpha Dart®治疗复发性皮肤鳞状细胞癌（cSCC）的首个上市前审批模块。这一重要进展标志着该创新疗法在监管审批流程中迈出了关键一步。\nAlpha Dart®作为一种新型放射治疗技术，专注于为复发型皮肤鳞状细胞癌患者提供精准靶向治疗。此次提交的模块涵盖了产品的核心数据，为后续审批奠定了坚实基础。\n该公司的突破性技术平台通过α粒子放射疗法直接作用于肿瘤细胞，在早期临床研究中展现出显著疗效。此次监管里程碑将加速该疗法为患者提供创新治疗选择的进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTSW","DRTS","BK4082"],"gpt_icon":0},{"id":"1160292703","title":"Alpha Tau獲得FDA批准啓動局部復發前列腺癌患者試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1160292703","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160292703?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 22:02","pubTimestamp":1764684124,"startTime":"0","endTime":"0","summary":"Alpha Tau获得FDA批准，启动针对局部复发前列腺癌患者的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","BK4082","DRTSW"],"gpt_icon":0},{"id":"1151041494","title":"Alpha Tau Medical成功治療美國多中心胰腺癌臨床試驗首例患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1151041494","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151041494?lang=zh_tw&edition=fundamental","pubTime":"2025-09-02 20:31","pubTimestamp":1756816268,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical成功治疗美国多中心胰腺癌临床试验首例患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","DRTSW","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}